U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Ofloxacin – Oral products
  1. Development Resources

Ofloxacin – Oral products

 

Minimum Inhibitory
Concentrations
(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Enterobacterales

M100 standard is recognized

Salmonella spp.

M100 standard is recognized

-

-

-

Pseudomonas aeruginosa

M100 standard is recognized

Staphylococcus aureus  (methicillin susceptible)

≤ 2

4

≥ 8

≥ 16

13-15

≤ 12

Haemophilus influenzae and parainfluenzae

M100 standard is recognized

Neisseria gonorrhoeae

≤ 0.25

0.5-1

≥ 2

≥ 31

25-30

≤ 24

Streptococcus pneumoniae

M100 standard is recognized

Streptococcus spp. β-Hemolytic Group

M100 standard is recognized

S = Susceptible; I = Intermediate; R = Resistant

Exceptions to the recognized standard

For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:

Other Non-Enterobacterales

Streptococcus spp. Viridans Group

Back to Top